Reference : Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: ...
Scientific journals : Article
Human health sciences : Surgery
Human health sciences : Urology & nephrology
http://hdl.handle.net/2268/5482
Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results
English
Krämer, Bernhard K. [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Del Castillo, Domingo [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Margreiter, Raimund [> > > >]
Sperschneider, Heide [> > > >]
Olbricht, Christoph J. [> > > >]
Ortuno, Joaquin [> > > >]
Sester, Urban [> > > >]
Kunzendorf, Ulrich [> > > >]
Dietl, Karl-Heinz [> > > >]
Bonomini, Vittorio [> > > >]
Rigotti, Paolo [> > > >]
Ronco, Claudio [> > > >]
Tabernero, Jose M. [> > > >]
Rivero, Manuel [> > > >]
Banas, Bernhard [> > > >]
Mühlbacher, Ferdinand [> > > >]
Arias, Manuel [> > > >]
Montagnino, Giuseppe [> > > >]
Dietl, K. H. [> > > >]
Ortuno, J. [> > > >]
Pascual, J. [> > > >]
Kammerl, M. [> > > >]
Sester, U.
Hauser, I.
Ponticelli, C.
Bonomini, V.
Arias, M.
Ancona, E.
Calconi, G.
Cambi, V.
La Greca, Giuseppe
Mosca, F.
Selvaggi, F.
Meurisse, Michel mailto
Detry, Olivier mailto
Molina, M. G.
Piccoli, G.
Salvadori, M.
Schilling, M.
Raedelli, C.
Arns, W.
Suarez, F.
Algarra, G. R.
Asensio, C.
Maiorca, R.
Ancona, G.
Sparacino, V.
Morales, J. M.
Gutierrez, J. A.
Lauzurica, R.
Verpooten, G. A.
Sennesael, J.
Heidecke, C.
Garcia, J.
Capdevila, L.
Abendroth, D.
Biesenbach, G.
Altieri, P.
Sorba, G.
Valente, U.
Castagneto, M.
Purroy, A.
Duhoux, P.
Jul-2008
Nephrology Dialysis Transplantation
Oxford University Press
23
7
2386-2392
Yes (verified by ORBi)
International
0931-0509
1460-2385
Oxford
United Kingdom
[en] kindey transplantation ; immunosuppression
[en] BACKGROUND: The European tacrolimus versus ciclosporin A microemulsion (CsA-ME) renal transplantation study showed that tacrolimus was significantly more effective in preventing acute rejection and had a superior cardiovascular risk profile at 6 months. METHODS: The endpoints of this investigator-initiated, observational, 36-month follow-up were acute rejection incidence rates, rates of patient and graft survival and renal function. An additional analysis was performed using the combined endpoints BPAR, graft loss and patient death. Data available from the original ITT population (557 patients; 286 tacrolimus and 271 CsA-ME) were analysed. RESULTS: A total of 231 tacrolimus and 217 CsA-ME patients participated. At 36 months, Kaplan-Meier-estimated BPAR-free survival rates were 78.8% in the tacrolimus group and 60.6% in the CsA-ME group, graft survival rates were 88.0% and 86.9% and patient survival rates were 96.6% and 96.7%, respectively. The estimated combined endpoint-free survival rate was 71.4% with tacrolimus and 55.4% with CsA-ME (P <or= 0.001, chi-square test). Significantly more CsA-ME patients crossed over to tacrolimus during the 3-year follow-up: 21.2% versus 2.6%, P <or= 0.0001, chi-square test. Most patients in the tacrolimus arm discontinued steroids and received monotherapy and fewer tacrolimus patients remained on a triple regimen. Mean serum creatinine concentration was 145.4 +/- 90.9 micromol/L with tacrolimus and 149.0 +/- 92.1 micromol/L with CsA-ME. Significantly more CsA-ME patients had a classified cholesterol value >6 mmol/L (26.3% versus 12.6%, P <or= 0.0003, chi-square test). CONCLUSIONS: Patients treated with tacrolimus had significantly higher combined endpoint-free survival rates and lower acute rejection rates with less immunosuppressive medication at 36 months.
Professionals ; Students ; General public
http://hdl.handle.net/2268/5482

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
NephrolDiaTx.2008.pdfNo commentaryPublisher postprint194.84 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.